Rhythm Pharmaceuticals (NASDAQ: RYTM) Receives 'Outperform' Rating Amid Strong Financial Performance

• Rhythm Pharmaceuticals (NASDAQ: RYTM) received an "Outperform" rating from Citigroup, with its stock trading at $105.78.
• The biopharmaceutical company reported a second-quarter loss of $0.73 per share, outperforming analyst estimates, and achieved $71.26 million in revenue, exceeding expectations by 6%.
• Strong global sales of IMCIVREE® and promising Phase 2 trial data for its investigational drug, RM-718, underscore the company's robust market adoption and future growth potential.

On August 5, 2026, analyst firm Citigroup restated its "Outperform" rating for Rhythm Pharmaceuticals (NASDAQ: RYTM) when the stock price was $105.78. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. It focuses on developing and commercializing treatments for rare genetic diseases that cause severe obesity and uncontrollable hunger.

The positive rating follows Rhythm Pharmaceuticals' recent financial report. The company posted a second-quarter loss of $0.73 per share. This performance is better than the Zacks Consensus Estimate of a $0.81 per share loss and an improvement from the $0.75 per share loss a year ago, as highlighted by Zacks Investment Research.

Revenue for the quarter reached $71.26 million, which is 6% above analyst expectations. This figure represents significant growth from the $48.50 million in revenue during the same period last year. This marks the fourth consecutive quarter that Rhythm Pharmaceuticals has surpassed revenue estimates.

This strong performance is driven by global sales of its product, IMCIVREE®. The drug's U.S. launch for acquired hypothalamic obesity is successful, with over 400 patient start forms recorded as of June 30, 2026. This indicates strong market adoption for the treatment.

Further supporting Rhythm Pharmaceuticals' outlook, its drug pipeline shows promise. Preliminary data from a Phase 2 trial for its investigational drug, RM-718, shows a mean BMI reduction of 11.6% in a small group of patients. This suggests potential for a future weekly treatment option.